Clinical Trials Logo

Fatigue in Multiple Sclerosis clinical trials

View clinical trials related to Fatigue in Multiple Sclerosis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05890885 Recruiting - Clinical trials for Fatigue in Multiple Sclerosis

MS Fatigue and tDCS on Fatigue in Multiple Sclerosis

MSfatDCS
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The available therapeutic strategies for Multiple Sclerosis (MS)-related symptoms are usually faced with limited efficacy and numerous side effects. Patients with MS frequently suffer from fatigue, affective symptoms, and cognitive deficits.

NCT ID: NCT03185065 Completed - Clinical trials for Fatigue in Multiple Sclerosis

Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis

TRIUMPHANT-MS
Start date: October 4, 2017
Phase: Phase 3
Study type: Interventional

Randomized, placebo-controlled, crossover, 4-sequence, 4-period, double-blind (participants and investigators), multicenter trial of 3 commonly used medications for treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS defined by McDonald Criteria.

NCT ID: NCT02286557 Not yet recruiting - Clinical trials for Fatigue in Multiple Sclerosis

Testing the Effects of Methylphenidate on Multiple Sclerosis

Start date: October 2014
Phase: Phase 2
Study type: Interventional

Up to 95% of individuals with Multiple Sclerosis report experiencing cognitive fatigue, characterized by a lack of energy, feelings of exhaustion, an the perception that one is unable to partake in daily activities. The goal of this project is to test whether methylphenidate (MP), a well-known psychostimulant, can effective treat fatigue experienced by individuals with MS. The current study will test the effect of MP on MS fatigue through a clinical trial. Every participant in the study will be exposed to both the drug and the placebo for a period of time. Both the investigators and participants will be unaware whether participants are receiving the drug or the placebo. Upon successful completion of the study, physicians will be able to evaluate the potential prescription of MP to treat fatigue in persons with MS based on solid research evidence. Importantly, MP is already an FDA approved widely used medication in multiple clinical populations.

NCT ID: NCT01490840 Completed - Clinical trials for Fatigue in Multiple Sclerosis

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis

PACE
Start date: November 2011
Phase: Phase 4
Study type: Interventional

This study will evaluate the effect of an individualized web-based physical training in fingolimod -treated patients.